JNJ

227.5

-0.9%↓

ABT

91.43

+0.09%↑

MDT

82.96

-0.35%↓

115.22

+0.92%↑

VEEV

158.38

+1.6%↑

JNJ

227.5

-0.9%↓

ABT

91.43

+0.09%↑

MDT

82.96

-0.35%↓

115.22

+0.92%↑

VEEV

158.38

+1.6%↑

JNJ

227.5

-0.9%↓

ABT

91.43

+0.09%↑

MDT

82.96

-0.35%↓

115.22

+0.92%↑

VEEV

158.38

+1.6%↑

JNJ

227.5

-0.9%↓

ABT

91.43

+0.09%↑

MDT

82.96

-0.35%↓

115.22

+0.92%↑

VEEV

158.38

+1.6%↑

JNJ

227.5

-0.9%↓

ABT

91.43

+0.09%↑

MDT

82.96

-0.35%↓

115.22

+0.92%↑

VEEV

158.38

+1.6%↑

Home・Aandelen Lijst・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Open

SectorGezondheidszorg

33.09 -3.08

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

32.5

Max

34.12

Belangrijke statistieken
By Trading Economics
Inkomsten	-14M -81M
Verkoop	75K 75K
EPS	-1.22
Winstmarge	-108,422.667
Werknemers	198
EBITDA	-7.8M -81M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+65.45% upside

Dividenden
By Dow Jones
Volgende Winsten	6 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	1.1B 2.7B
Vorige openingsprijs	36.17
Vorige sluitingsprijs	33.09

Nieuwssentiment

By Acuity

50%

178 / 348 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

18.91 / 20.63 Steun & Weerstand

Celldex Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 apr 2026, 00:00 UTC

Winsten

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

24 apr 2026, 00:00 UTC

Winsten

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

23 apr 2026, 23:47 UTC

Marktinformatie

Gold Edges Lower Amid Ongoing Concerns Over Higher Inflation -- Market Talk

23 apr 2026, 23:43 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

23 apr 2026, 23:43 UTC

Marktinformatie

Global Equities Roundup: Market Talk

23 apr 2026, 23:43 UTC

Marktinformatie

Nikkei May Decline Amid Uncertainty Over U.S.-Iran Conflict -- Market Talk

23 apr 2026, 23:13 UTC

Acquisities, Fusies, Overnames

Trump on Spirit Airlines: 'I Think We'd Just Buy It' -- Update

23 apr 2026, 22:33 UTC

Winsten

Intel Shares Jump 20% as AI Agents Drive Big Growth -- WSJ

23 apr 2026, 22:17 UTC

Winsten

PLS Executed Offtake Agreement With Ronbay

23 apr 2026, 22:17 UTC

Winsten

PLS Secured Up to A$38.1M in Australia Government ARENA Grant Funding

23 apr 2026, 22:16 UTC

Winsten

PLS Commences Commissioning of Midstream Demonstration Plant

23 apr 2026, 22:15 UTC

Winsten

PLS Group Reaffirms FY26 Guidance for All Metrics

23 apr 2026, 22:14 UTC

Winsten

PLS Group 3Q Cash Margin From Operations A$461M at March 31

23 apr 2026, 22:14 UTC

Winsten

PLS Group 3Q Cash Balance A$1.455 Billion at March 31

23 apr 2026, 22:13 UTC

Winsten

PLS Group 3Q Unit Operating Cost A$733/Ton CIF, Up 2% on 2Q

23 apr 2026, 22:12 UTC

Winsten

Correct: PLS Group 3Q Unit Operating Cost A$520/Ton FOB, Down 11% on 2Q

23 apr 2026, 22:12 UTC

Winsten

PLS Group 3Q Unit Operating Cost US$520/Ton FOB, Down 11% on 2Q

23 apr 2026, 22:11 UTC

Winsten

PLS Group 3Q Realized Price US$1,867/Ton, Up 61% on 2Q

23 apr 2026, 22:10 UTC

Winsten

PLS Group 3Q Revenue A$567,000, Up 52% on 2Q

23 apr 2026, 22:09 UTC

Winsten

PLS Group 3Q Sales 195,700 Tons, Down 16% on 2Q

23 apr 2026, 22:08 UTC

Winsten

PLS Group 3Q Production 232,400 Tons, Up 12% on 2Q

23 apr 2026, 22:04 UTC

Winsten

Intel Sales Rise 7% as AI Agents Drive Growth -- WSJ

23 apr 2026, 21:56 UTC

Marktinformatie

Winsten

Intel Points to Growing Role of CPUs Amid AI Shifts -- Market Talk

23 apr 2026, 21:48 UTC

Acquisities, Fusies, Overnames

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

23 apr 2026, 21:27 UTC

Winsten

Intel CFO: All Demand Signals Point to Growing Role of CPUs in AI Era

23 apr 2026, 21:25 UTC

Winsten

Intel CFO Expects Factories to Continue Increasing Supply in 3Q, 4Q, but at More Measured Pace Than Previously Expected

23 apr 2026, 21:24 UTC

Winsten

SAP Stock Rebounds From Software Slaughter. The Cloud Boosted Europe's Tech Titan. -- Barrons.com

23 apr 2026, 21:24 UTC

Winsten

Blackstone Stock Falls After Earnings. Private Credit Remains in Focus. -- Barrons.com

23 apr 2026, 21:21 UTC

Winsten

Intel to Look for Unconventional Way to Boost Manufacturing Capacity Through Musk's Terafab Project, CEO Says

23 apr 2026, 21:21 UTC

Winsten

Intel CEO: He, Elon Musk Believe Global Semiconductor Supply Isn't Keeping Up With Accelerating Demand

Peer Vergelijking

Prijswijziging

Celldex Therapeutics Inc Prognose

Koersdoel

By TipRanks

65.45% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 56.6 USD 65.45%

Hoogste 90 USD

Laagste 34 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Celldex Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Gebaseerd op 11 analisten die aandelenratings hebben gegeven aan Celldex Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

18.91 / 20.63Steun & Weerstand

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

178 / 348 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.